LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Metagenomics Enables Rapid Respiratory Infection Testing in ICU Patients

By LabMedica International staff writers
Posted on 28 Feb 2024
Print article
Image: Genetic testing offers potential for faster diagnosis for patients with infectious respiratory conditions (Photo courtesy of 123RF)
Image: Genetic testing offers potential for faster diagnosis for patients with infectious respiratory conditions (Photo courtesy of 123RF)

Patients with respiratory infectious diseases admitted to intensive care units urgently need appropriate medication, yet microbiologists typically require around three days to identify the responsible pathogens. Now, a new technology could offer a faster diagnostic solution for patients struggling with respiratory infections.

Researchers from Guy’s and St Thomas’ NHS Foundation Trust (GSTT, London, UK) have trialed a new technology that accelerates the genetic testing process for patients with suspected respiratory infectious diseases. This advanced approach, known as metagenomics, sequences genetic material from a comprehensive range of microorganisms, including bacteria, viruses, and fungi, potentially responsible for the infection. Remarkably, results are available in just seven hours, enabling same-day administration of accurate and effective treatments.

Unlike other tests, metagenomic testing can detect all present microorganisms, not limited to those specifically being sought or suspected by clinicians of causing the infection. The researchers have secured additional funding to extend this rapid genetic testing to a broader patient base. This expansion builds upon the initial successful pilot, which demonstrated its potential to enhance treatment for nearly half of the participants. The new funding will facilitate the implementation of this technology in multiple hospitals across the UK over the next two years. The aim is to monitor and curtail the spread of respiratory diseases, ultimately aiding in the prevention of new outbreaks.

“It is vital that the sickest patients in our intensive care unit receive the right medication as quickly as possible,” said Ian Abbs, Chief Executive at Guy’s and St Thomas’ and Co-Chair of the South East Genomic Medicine Service. “This new genetic test can make that happen and we are delighted that we now have funding to ensure other intensive care units, and their patients, can also benefit.”

Related Links:
GSTT

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.